NASDAQ:QTRX • US74766Q1013
The current stock price of QTRX is 4.76 USD. Today QTRX is down by -4.99%. In the past month the price decreased by -20.4%. In the past year, price decreased by -32.58%.
ChartMill assigns a technical rating of 0 / 10 to QTRX. When comparing the yearly performance of all stocks, QTRX is a bad performer in the overall market: 90.45% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to QTRX. The financial health of QTRX is average, but there are quite some concerns on its profitability.
On March 2, 2026 QTRX reported an EPS of -0.49 and a revenue of 43.85M. The company missed EPS expectations (-6.75% surprise) and beat revenue expectations (12.73% surprise).
9 analysts have analysed QTRX and the average price target is 7.65 USD. This implies a price increase of 60.71% is expected in the next year compared to the current price of 4.76.
For the next year, analysts expect an EPS growth of 39.08% and a revenue growth 28.28% for QTRX
Over the last trailing twelve months QTRX reported a non-GAAP Earnings per Share(EPS) of -2.21. The EPS decreased by -114.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.59% | ||
| ROE | -36.23% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.19 | 184.15B | ||
| DHR | DANAHER CORP | 21.93 | 137.935B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 130.84 | 44.512B | ||
| A | AGILENT TECHNOLOGIES INC | 16.68 | 32.629B | ||
| WAT | WATERS CORP | 19.5 | 29.189B | ||
| IQV | IQVIA HOLDINGS INC | 12.71 | 28.803B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 24.9 | 24.984B | ||
| ILMN | ILLUMINA INC | 22.09 | 18.577B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 28.52 | 17.159B | ||
| MEDP | MEDPACE HOLDINGS INC | 25.46 | 13.558B | ||
| RVTY | REVVITY INC | 15.37 | 10.021B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 9.418B | ||
| TECH | BIO-TECHNE CORP | 23.13 | 8.389B |
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2017-12-07. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
IPO: 2017-12-07
QUANTERIX CORP
900 Middlesex Turnpike
Billerica MASSACHUSETTS 01821 US
CEO: E. Kevin Hrusovsky
Employees: 471
Phone: 13026587581
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 471 full-time employees. The company went IPO on 2017-12-07. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
The current stock price of QTRX is 4.76 USD. The price decreased by -4.99% in the last trading session.
QTRX does not pay a dividend.
QTRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
QTRX stock is listed on the Nasdaq exchange.
QUANTERIX CORP (QTRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.21).
QUANTERIX CORP (QTRX) has a market capitalization of 222.34M USD. This makes QTRX a Micro Cap stock.